Trial Profile
Safety and immunogenicity of a booster dose of dTPa Vaccine (Boostrix) co-admnd. with Aventis Pasteur's meningococcal (serogroups A, C, Y and W-135) polysaccharide vaccine (Menactra) vs admn. of either vaccine alone in healthy adolescents
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs DTaP vaccine (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate
- Indications Diphtheria; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections; Pertussis; Tetanus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 03 Feb 2012 Actual patient number changed from 1341 to 1376 as reported by ClinicalTrials.gov.
- 14 Oct 2006 New trial record.